Stay updated on Lenvatinib Combo With Pembrolizumab in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib Combo With Pembrolizumab in Endometrial Cancer Clinical Trial page.

Latest updates to the Lenvatinib Combo With Pembrolizumab in Endometrial Cancer Clinical Trial page
- Check7 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, pricing, or availability.SummaryDifference0.1%
- Check15 days agoChange DetectedThe web page has undergone significant updates, including the addition of numerous facility names and locations across various countries, while also removing several previously listed locations. Notably, the names of drugs such as lenvatinib and pembrolizumab have been retained, indicating a focus on medical content.SummaryDifference21%
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.0%
- Check36 days agoChange DetectedThe web page has been updated from version v2.16.10 to v2.16.11.SummaryDifference0.0%
- Check43 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.5%
- Check50 days agoChange DetectedThe page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, and includes a new section on HHS Vulnerability Disclosure.SummaryDifference0.1%
Stay in the know with updates to Lenvatinib Combo With Pembrolizumab in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib Combo With Pembrolizumab in Endometrial Cancer Clinical Trial page.